Migraine Briefs

Migraine: Erenumab reduces acute medication usage in a real-world setting


 

Key clinical point: Erenumab significantly reduced acute medication use and health care resource utilization (HCRU) among patients with migraine in a real-world setting in the U.S.A.

Major finding: The mean number of claims (rate ratio [RR], 0.77) and number of patients using acute medication (both P less than .0001) significantly declined in 6 months postinitiation of erenumab. Similarly, 6-month HCRU of migraine-specific office visits (RR, 0.77) and all-cause office visits (RR, 0.92) decreased significantly (both P less than .0001).

Study details: Data come from a retrospective, exploratory analysis of 3,171 adult patients with migraine who initiated erenumab and had at least 3 doses in the 6 months post-index period.

Disclosures: The study was supported by Novartis Pharma AG. SJ Tepper reported serving as a consultant and/or on advisory boards, receiving grants, and CME honoraria from multiple sources. Some of the authors declared being employees and shareholders of Novartis.

Source: Tepper SJ et al. J Headache Pain. 2021 Apr 19. doi: 10.1186/s10194-021-01238-2 .

Recommended Reading

Nonpharmacological interventions can effectively treat pediatric migraine
Migraine ICYMI
Eptinezumab safe and effective for treatment of migraine
Migraine ICYMI
Transcranial brain stimulation can modulate placebo and nocebo experiences
Migraine ICYMI
Headache on the Hill goes virtual
Migraine ICYMI
Migraine: Cardiovascular risk status does not influence safety and efficacy of ubrogepant
Migraine ICYMI
Migraine: Lasmiditan more effective when initiated at mild pain intensity
Migraine ICYMI
Real-world evidence supports benefits of erenumab for chronic migraine
Migraine ICYMI
Fremanezumab effective in patients with difficult-to-treat migraine
Migraine ICYMI
Race, ethnicity, and socioeconomics are often barriers to migraine care
Migraine ICYMI
Comparative efficacy and safety of CGRP monoclonal antibodies in migraine
Migraine ICYMI